Shield Therapeutics (AIM: STX)

Currency in GBP

Last close As at 30/11/2023


0.05 (0.83%)

Market capitalisation


Shield Therapeutics is a commercial-stage pharmaceutical company. Its proprietary product, Feraccru/Accrufer, is approved by the EMA and FDA for iron deficiency. Outside the US, Feraccru is marketed internationally through Shield and its commercial partners. Shield signed a US co-commercialisation deal with Nasdaq-listed Viatris in December 2022.

The market for iron deficiency is substantial and Feraccru/Accrufer is a unique oral formulation of iron developed to overcome the side-effect profile of salt-based oral iron therapies and provides an alternative treatment to intravenously administered iron.

Latest Insights

View More



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Greg Madison


  • Paul Spoors

    Group company controller and acting CFO

Balance Sheet

Forecast net cash (US$m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual 2.5 (42.4) (28.8)
Relative (0.4) (42.1) (27.7)
52 week high/low 12.5p/5.8p


Shield Therapeutics is a UK-headquartered commercial-stage speciality pharmaceutical company focused on the commercialisation of Feraccru/Accrufer (oral ferric maltol), approved by the EMA and FDA to treat iron deficiency in adults, with or without anaemia. Shield launched the product in the US in July 2021 as part of its self-commercialisation strategy. However, it signed a US co-commercialisation deal for Accrufer with Viatris in December 2022. The commercialisation of Feraccru in Europe, Australia and New Zealand is managed by distribution partner Norgine, and it has been licensed to ASK Pharm in China, Korea Pharma in South Korea and KYE Pharma in Canada. Q223 was a strong quarter with 51% q-o-q growth in US prescriptions to 15,800 and led to stronger management guidance of ~80% sequential growth in Q323 and anticipated ~100–130k US prescriptions in FY23. Supported by the recent $20m debt financing and $6.2m equity raise, we believe Shield is sufficiently funded to profitability in FY25.

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2021A N/A N/A N/A N/A N/A N/A
2022A 5.5 (28.7) (31.2) (12.3) N/A N/A
2023E 22.9 (27.9) (29.7) (3.8) N/A N/A
2024E 74.8 (12.0) (15.2) (1.8) N/A N/A




Deutsches Eigenkapitalforum (EKF) 2023 healthcare




VolitionRx – Decoding the DNA of cancer 



ASCO 2023 key takeaways



Machine learning in drug development

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free